vs
QUAKER CHEMICAL CORP（KWR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是QUAKER CHEMICAL CORP的1.6倍（$772.1M vs $468.5M），Revvity净利率更高（12.7% vs 4.4%，领先8.3%），Revvity同比增速更快（5.9% vs 5.5%），Revvity自由现金流更多（$161.8M vs $24.3M），过去两年Revvity的营收复合增速更高（9.0% vs -0.1%）
奎克化学（现业务名称为奎克好富顿）是1918年成立的美国化工企业，总部位于宾夕法尼亚州康舍霍肯。公司在全球21个国家设有35个运营点，超半数净销售额来自美国境外，主营面向钢铁、铝加工、金属加工、汽车、采矿、航空航天、管材制造、制罐等领域的工业工艺流体产品。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
KWR vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$468.5M
营收增速更快
RVTY
高出0.4%
5.5%
净利率更高
RVTY
高出8.3%
4.4%
自由现金流更多
RVTY
多$137.5M
$24.3M
两年增速更快
RVTY
近两年复合增速
-0.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $468.5M | $772.1M |
| 净利润 | $20.7M | $98.4M |
| 毛利率 | 35.3% | — |
| 营业利润率 | 6.7% | 14.5% |
| 净利率 | 4.4% | 12.7% |
| 营收同比 | 5.5% | 5.9% |
| 净利润同比 | 45.9% | 3.9% |
| 每股收益（稀释后） | $1.16 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KWRRVTY
| Q4 25 | $468.5M | $772.1M | ||
| Q3 25 | $493.8M | $698.9M | ||
| Q2 25 | $483.4M | $720.3M | ||
| Q1 25 | $442.9M | $664.8M | ||
| Q4 24 | $444.1M | $729.4M | ||
| Q3 24 | $462.3M | $684.0M | ||
| Q2 24 | $463.6M | $691.7M | ||
| Q1 24 | $469.8M | $649.9M |
净利润KWRRVTY
| Q4 25 | $20.7M | $98.4M | ||
| Q3 25 | $30.5M | $46.7M | ||
| Q2 25 | $-66.6M | $53.9M | ||
| Q1 25 | $12.9M | $42.2M | ||
| Q4 24 | $14.2M | $94.6M | ||
| Q3 24 | $32.3M | $94.4M | ||
| Q2 24 | $34.9M | $55.4M | ||
| Q1 24 | $35.2M | $26.0M |
毛利率KWRRVTY
| Q4 25 | 35.3% | — | ||
| Q3 25 | 36.6% | 53.6% | ||
| Q2 25 | 35.5% | 54.5% | ||
| Q1 25 | 36.4% | 56.5% | ||
| Q4 24 | 35.2% | — | ||
| Q3 24 | 37.3% | 56.3% | ||
| Q2 24 | 37.9% | 55.7% | ||
| Q1 24 | 38.7% | 54.6% |
营业利润率KWRRVTY
| Q4 25 | 6.7% | 14.5% | ||
| Q3 25 | 9.4% | 11.7% | ||
| Q2 25 | -10.9% | 12.6% | ||
| Q1 25 | 6.2% | 10.9% | ||
| Q4 24 | 6.5% | 16.3% | ||
| Q3 24 | 11.2% | 14.3% | ||
| Q2 24 | 12.6% | 12.4% | ||
| Q1 24 | 11.8% | 6.8% |
净利率KWRRVTY
| Q4 25 | 4.4% | 12.7% | ||
| Q3 25 | 6.2% | 6.7% | ||
| Q2 25 | -13.8% | 7.5% | ||
| Q1 25 | 2.9% | 6.4% | ||
| Q4 24 | 3.2% | 13.0% | ||
| Q3 24 | 7.0% | 13.8% | ||
| Q2 24 | 7.5% | 8.0% | ||
| Q1 24 | 7.5% | 4.0% |
每股收益（稀释后）KWRRVTY
| Q4 25 | $1.16 | $0.86 | ||
| Q3 25 | $1.75 | $0.40 | ||
| Q2 25 | $-3.78 | $0.46 | ||
| Q1 25 | $0.73 | $0.35 | ||
| Q4 24 | $0.81 | $0.77 | ||
| Q3 24 | $1.81 | $0.77 | ||
| Q2 24 | $1.94 | $0.45 | ||
| Q1 24 | $1.95 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $179.8M | $919.9M |
| 总债务越低越好 | $834.9M | — |
| 股东权益账面价值 | $1.4B | $7.3B |
| 总资产 | $2.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.61× | — |
8季度趋势，按日历期对齐
现金及短期投资KWRRVTY
| Q4 25 | $179.8M | $919.9M | ||
| Q3 25 | $172.0M | $931.4M | ||
| Q2 25 | $201.9M | $991.8M | ||
| Q1 25 | $186.2M | $1.1B | ||
| Q4 24 | $188.9M | $1.2B | ||
| Q3 24 | $212.1M | $1.2B | ||
| Q2 24 | $188.6M | $2.0B | ||
| Q1 24 | $195.8M | $1.7B |
总债务KWRRVTY
| Q4 25 | $834.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $669.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益KWRRVTY
| Q4 25 | $1.4B | $7.3B | ||
| Q3 25 | $1.4B | $7.4B | ||
| Q2 25 | $1.3B | $7.6B | ||
| Q1 25 | $1.4B | $7.6B | ||
| Q4 24 | $1.4B | $7.7B | ||
| Q3 24 | $1.4B | $7.9B | ||
| Q2 24 | $1.4B | $7.9B | ||
| Q1 24 | $1.4B | $7.8B |
总资产KWRRVTY
| Q4 25 | $2.8B | $12.2B | ||
| Q3 25 | $2.8B | $12.1B | ||
| Q2 25 | $2.8B | $12.4B | ||
| Q1 25 | $2.7B | $12.4B | ||
| Q4 24 | $2.6B | $12.4B | ||
| Q3 24 | $2.7B | $12.8B | ||
| Q2 24 | $2.7B | $13.4B | ||
| Q1 24 | $2.7B | $13.4B |
负债/权益比KWRRVTY
| Q4 25 | 0.61× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.49× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $46.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $24.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 5.2% | 21.0% |
| 资本支出强度资本支出/营收 | 4.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.25× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $80.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流KWRRVTY
| Q4 25 | $46.5M | $182.0M | ||
| Q3 25 | $51.4M | $138.5M | ||
| Q2 25 | $41.6M | $134.3M | ||
| Q1 25 | $-3.0M | $128.2M | ||
| Q4 24 | $63.1M | $174.2M | ||
| Q3 24 | $68.0M | $147.9M | ||
| Q2 24 | $46.3M | $158.6M | ||
| Q1 24 | $27.2M | $147.6M |
自由现金流KWRRVTY
| Q4 25 | $24.3M | $161.8M | ||
| Q3 25 | $38.0M | $120.0M | ||
| Q2 25 | $33.6M | $115.5M | ||
| Q1 25 | $-15.4M | $112.2M | ||
| Q4 24 | $40.6M | $149.8M | ||
| Q3 24 | $59.8M | $125.6M | ||
| Q2 24 | $39.6M | $136.6M | ||
| Q1 24 | $22.8M | $129.7M |
自由现金流率KWRRVTY
| Q4 25 | 5.2% | 21.0% | ||
| Q3 25 | 7.7% | 17.2% | ||
| Q2 25 | 7.0% | 16.0% | ||
| Q1 25 | -3.5% | 16.9% | ||
| Q4 24 | 9.1% | 20.5% | ||
| Q3 24 | 12.9% | 18.4% | ||
| Q2 24 | 8.6% | 19.7% | ||
| Q1 24 | 4.8% | 20.0% |
资本支出强度KWRRVTY
| Q4 25 | 4.7% | 2.6% | ||
| Q3 25 | 2.7% | 2.6% | ||
| Q2 25 | 1.6% | 2.6% | ||
| Q1 25 | 2.8% | 2.4% | ||
| Q4 24 | 5.1% | 3.4% | ||
| Q3 24 | 1.8% | 3.3% | ||
| Q2 24 | 1.4% | 3.2% | ||
| Q1 24 | 0.9% | 2.7% |
现金转化率KWRRVTY
| Q4 25 | 2.25× | 1.85× | ||
| Q3 25 | 1.69× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | -0.24× | 3.03× | ||
| Q4 24 | 4.45× | 1.84× | ||
| Q3 24 | 2.10× | 1.57× | ||
| Q2 24 | 1.33× | 2.87× | ||
| Q1 24 | 0.77× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KWR
| Other | $260.7M | 56% |
| Metalworking And Other | $146.4M | 31% |
| Metals | $61.4M | 13% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
